Mira Pharmaceuticals Inc (MIRA)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
$0.56+8.34%
Close 2026-11-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
QuarterlyIQ Insights · MIRA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-11-04 · Compared with 11 industry peers
MIRA — litigation filed
Dated 2026-10-28
Regulation FD Disclosure. MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide On October 28, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) announced initial positive proof-of-concept results from an exploratory pilot study evaluating SKNY-1, its investigational oral drug candidate for obesity and metabolic disorders. Conducted in an established diet-induced obesity…
Why it matters: The mouse study found less lean-mass loss and weight regain than the semaglutide group. Longer studies can test if those results last.
Supportive ifA longer study in animals finds weight loss with no significant loss of lean mass. It also finds little weight regain after treatment stops.
Worry ifA longer study finds significant loss of lean mass or weight regain like that in the semaglutide group.
Why it matters: An IND filing would move MIRA-55 closer to human testing. MIRA says remaining studies and regulatory work must first be completed.
Supportive ifMIRA files the MIRA-55 IND with the FDA in Q1 2027.
Worry ifMIRA reports that some studies are incomplete or that the Q1 2027 filing target has slipped.
Why it matters: Ketamir-2 has completed Phase 1, and MIRA says its Phase 2a program is moving toward site start. A delay would slow the next clinical test.
Supportive ifMIRA reports that a Phase 2a site is open or that the first patient has enrolled.
Worry ifMIRA reports that site start is delayed or that the revised study protocol has not cleared review.
Why it matters: MIRA plans to measure energy use directly. Positive results would support its idea that SKNY-1 can reduce weight without cutting food intake.
Supportive ifThe next study finds higher energy use with SKNY-1. It confirms weight loss without a significant drop in food intake.
Worry ifThe next study finds no rise in energy use, or weight loss comes with a significant drop in food intake.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$302 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $660 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,823 loss on $10,000 · 68.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.